Neuropeptide y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma

Peptides

Volumn 75, Issue , 2016, Pages 80-95

  Wong, Pok Fai ^a   Gall, Margaret G ^a   Bachovchin, William W ^b   McCaughan, Geoffrey W ^a   Keane, Fiona M ^a   Gorrell, Mark D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Dipeptidyl peptidase; Fibroblast activation protein; Kallikrein; Liver disease; Protease substrates

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FIBROBLAST ACTIVATION PROTEIN; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PEPTIDE YY; PEPTIDE YY [3-36]; PLASMA KALLIKREIN; SUBSTANCE P; UNCLASSIFIED DRUG; DPP4 PROTEIN, HUMAN; GELATINASE; MEMBRANE PROTEIN; NEUROPEPTIDE Y RECEPTOR; PROTEINASE INHIBITOR; SEPRASE; SERINE PROTEINASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME SPECIFICITY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MESENCHYME CELL; MOUSE; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SPECIES DIFFERENCE; STROMA CELL; TISSUE LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CHEMISTRY; KINETICS; KNOCKOUT MOUSE; LIVER; LIVER TUMOR; METABOLISM; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DIPEPTIDYL PEPTIDASE 4; GELATINASES; HUMANS; KINETICS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPEPTIDE Y; PROTEASE INHIBITORS; PROTEOLYSIS; RECEPTORS, NEUROPEPTIDE Y; SERINE ENDOPEPTIDASES; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84949569597     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2015.11.004     Document Type: Article

References (57)

1. K.S. Abass Experimental measurements for the effect of dilution procedure in blood esterases as animals biomarker for exposure to OP compounds Biomed. Res. Int. 2014 451982 2014
2. K. Abid, B. Rochat, P.G. Lassahn, R. Stöcklin, S. Michalet, N. Brakch, J.F. Aubert, B. Vatansever, P. Tella, I. De Meester, and E. Grouzmann Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein J. Biol. Chem. 284 2009 24715 24724
3. K. Aertgeerts, I. Levin, L. Shi, G.P. Snell, A. Jennings, G.S. Prasad, Y. Zhang, M.L. Kraus, S. Salakian, V. Sridhar, R. Wijnands, and M.G. Tennant Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha J. Biol. Chem. 280 2005 19441 19444
4. S. Bando, T. Soeki, T. Matsuura, S. Yagi, D. Fukuda, Y. Hirotsugu, T. Wakatsuki, M. Shimabukuro, K. Kangawa, and M. Sata Plasma brain natriuretic peptide (BNP) level is elevated in patients with cancer Eur. Heart J. 34 2013 4572
5. A. Belenky, A. Smith, B. Zhang, S. Lin, N. Despres, A.H. Wu, and B.I. Bluestein The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma Clin. Chim. Acta 340 2004 163 172
6. C.A. Borgoño, I.P. Michael, and E.P. Diamandis Human tissue kallikreins: physiologic roles and applications in cancer Mol. Cancer Res. 2 2004 257 280
7. D. Cassiman, L. Libbrecht, V. Desmet, C. Denef, and T. Roskams Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers J. Hepatol. 36 2002 200 209
8. G. Cox, E. Kable, A. Jones, I. Fraser, F. Manconi, and M.D. Gorrell 3-dimensional imaging of collagen using second harmonic generation J. Struct. Biol. 141 2003 53 62
9. D.M. Dickey, and L.R. Potter Human B-type natriuretic peptide is not degraded by meprin A Biochem. Pharmacol. 80 2010 1007 1011
10. O. Dohi, H. Ohtani, M. Hatori, E. Sato, M. Hosaka, H. Nagura, E. Itoi, and S. Kokubun Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours Histopathology 55 2009 432 440
11. D.J. Drucker Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 30 2007 1335 1343
12. C.Y. Edosada, C. Quan, C. Wiesmann, T. Tran, D. Sutherlin, M. Reynolds, J.M. Elliott, H. Raab, W. Fairbrother, and B.B. Wolf Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity J. Biol. Chem. 281 2006 7437 7444
13. C. Feig, J.O. Jones, M. Kraman, R.J. Wells, A. Deonarine, D.S. Chan, C.M. Connell, E.W. Roberts, Q. Zhao, O.L. Caballero, S.A. Teichmann, T. Janowitz, D.I. Jodrell, D.A. Tuveson, and D.T. Fearon Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc. Natl. Acad. Sci. U. S. A. 110 2010 20212 20217
14. S.L. Friedman Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury J. Biol. Chem. 275 2000 2247 2250
15. M.G. Gall, Y. Chen, A.J. Vieira de Ribeiro, H. Zhang, C.G. Bailey, D.S. Spielman, D.M. Yu, and M.D. Gorrell Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality PLoS One 8 2013 e78378
16. M.D. Gorrell Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders Clin. Sci. 108 2005 277 292
17. M.D. Gorrell, and J. Park Fibroblast activation protein alpha N.D. Rawlings, G. Salvesen, Handbook of Proteolytic Enzymes Vol. 3 2013 Elsevier London, United Kingdom 3395 3401
18. E. Grouzmann, M. Monod, B. Landis, S. Wilk, N. Brakch, K. Nicoucar, R. Giger, D. Malis, I. Szalay-Quinodoz, C. Cavadas, D.R. Morel, and J.S. Lacroix Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa FASEB J. 16 2002 1132 1134
19. E.J. Hamson, F.M. Keane, S. Tholen, O. Schilling, and M.D. Gorrell Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy Proteomics Clin. Appl. 8 2014 454 463
20. D.M. Heublein, B.K. Huntley, G. Boerrigter, A. Cataliotti, S.M. Sandberg, M.M. Redfield, and J.C. Burnett Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide Hypertension 49 2007 1114 1119
21. C.C. Jia, T.T. Wang, W. Liu, B.S. Fu, X. Hua, G.Y. Wang, T.J. Li, X. Li, X.Y. Wu, Y. Tai, J. Zhou, G.H. Chen, and Q. Zhang Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion PLoS One 8 2013 e63243
22. M.J. Ju, S.J. Qiu, J. Fan, Y.S. Xiao, Q. Gao, J. Zhou, Y.W. Li, and Z.Y. Tang Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection Am. J. Clin. Pathol. 131 2009 498 510
23. F.M. Keane, S. Chowdhury, T.-W. Yao, N.A. Nadvi, M.G. Gall, Y. Chen, B. Osborne, A.J. Vieira de Ribeiro, W.B. Church, G.W. McCaughan, M.D. Gorrell, and D.M.T. Yu Targeting dipeptidyl peptidase-4 (DPP-4) and fibroblast activation protein (FAP) for diabetes and cancer therapy B. Dunn, Proteinases as Drug Targets 2012 Royal Society of Chemistry Cambridge, United Kingdom
24. F.M. Keane, N.A. Nadvi, T.-W. Yao, and M.D. Gorrell Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α FEBS J. 278 2011 1316 1332
25. F.M. Keane, T.-W. Yao, S. Seelk, M.G. Gall, S. Chowdhury, S.E. Poplawski, J.H. Lai, Y. Li, W. Wu, P. Farrell, A.J. Vieira de Ribeiro, B. Osborne, D.M. Yu, D. Seth, K. Rahman, P. Haber, A.K. Topaloglu, C. Wang, S. Thomson, A. Hennessy, J. Prins, S.M. Twigg, S.V. McLennan, G.W. McGaughan, W.W. Bachovchin, and M.D. Gorrell Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs FEBS Open Bio. 4 2014 43 54
26. T. Kelly, Y. Huang, A.E. Simms, and A. Mazur Fibroblast activation protein-α: a key modulator of the microenvironment in multiple pathologies Int. Rev. Cell Mol. Biol. 297 2012 83 116
27. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, J.K. Wu, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 48 2005 141 151
28. G.J. Kim, H. Rhee, J.E. Yoo, J.E. Ko, J.S. Lee, H. Kim, J.S. Choi, and Y.N. Park Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior PLoS One 9 2014 e105094
29. M. Kirby, D.M.T. Yu, S.P. O'Connor, and M.D. Gorrell Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition Clin. Sci. 118 2010 31 41
30. M. Kraman, P.J. Bambrough, J.N. Arnold, E.W. Roberts, L. Magiera, J.O. Jones, A. Gopinathan, D.A. Tuveson, and D.T. Fearon Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha Science 330 2010 827 830
31. M.G. Lawrence, J. Lai, and J.A. Clements Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus Endocr. Rev. 31 2010 407 446
32. K.N. Lee, K.W. Jackson, V.J. Christiansen, C.S. Lee, J.G. Chun, and P.A. McKee Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein Blood 107 2006 1397 1404
33. M.T. Levy, G.W. McCaughan, C.A. Abbott, J.E. Park, A.M. Cunningham, E. Müller, W.J. Rettig, and M.D. Gorrell Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis Hepatology 29 1999 1768 1778
34. M.T. Levy, G.W. McCaughan, G. Marinos, and M.D. Gorrell Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection Liver 22 2002 93 101
35. C. Lu, J.U. Tilan, L. Everhart, M. Czarnecka, S.J. Soldin, D.R. Mendu, D. Jeha, J. Hanafy, C.K. Lee, J. Sun, E. Izycka-Swieszewska, J.A. Toretsky, and J. Kitlinska Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy J. Biol. Chem. 286 2011 27494 27505
36. Y. Matsumoto, G.A. Bishop, and G.W. McCaughan Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver Hepatology 15 1992 1048 1053
37. M. Muñoz, and R. Coveñas Involvement of substance P and the NK-1 receptor in cancer progression Peptides 48 2013 1 9
38. J. Niedermeyer, M. Kriz, F. Hilberg, P. Garin-Chesa, U. Bamberger, M.C. Lenter, J. Park, B. Viertel, H. Püschner, M. Mauz, W.J. Rettig, and A. Schnapp Targeted disruption of mouse fibroblast activation protein Mol. Cell. Biol. 20 2000 1089 1094
39. B. Osborne, T.-W. Yao, X.M. Wang, Y. Chen, L.D. Kotan, N.A. Nadvi, M. Herdem, G.W. McCaughan, J. Allen, D.M. Yu, A.K. Topaloglu, and M.D. Gorrell A rare variant in human fibroblast activation protein associated with ER stress, loss of function and loss of cell surface localisation Biochim. Biophys. Acta 1844 2014 1248 1259
40. M.R. Pitman, M.L. Sulda, B. Kuss, and C.A. Abbott Dipeptidyl peptidase 8 and 9 - guilty by association? Front. Biosci. 14 2009 3619 3633
41. S.E. Poplawski, J.H. Lai, Y. Li, Z. Jin, Y. Liu, W. Wu, Y. Wu, Y. Zhou, J.L. Sudmeier, D.G. Sanford, and W.W. Bachovchin Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase J. Med. Chem. 56 2013 3467 3477
42. E. Prakoso, J.E. Tirnitz-Parker, A.D. Clouston, Z. Kayali, A. Lee, E.K. Gan, G.A. Ramm, J.G. Kench, D.G. Bowen, J.K. Olynyk, G.W. McCaughan, and N.A. Shackel Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation Liver Transpl. 20 2014 1508 1519
43. W.J. Rettig, S.L. Su, S.R. Fortunato, M.J. Scanlan, B.K. Raj, P. Garin-Chesa, J.H. Healey, and L.J. Old Fibroblast activation protein: purification, epitope mapping and induction by growth factors Int. J. Cancer 58 1994 385 392
44. M. Ruscica, E. Dozio, M. Motta, and P. Magni Relevance of the neuropeptide Y system in the biology of cancer progression Curr. Top. Med. Chem. 7 2007 1682 1691
45. R.J. Snow, W.W. Bachovchin, R.W. Barton, S.J. Campbell, S.J. Coutts, D.M. Freeman, W.G. Gutheil, T.A. Kelly, C.A. Kennedy, D.A. Krolikowski, S.F. Leonard, C.A. Pargellis, L. Tong, and J. Adams Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV: identification of a cyclic species containing a BN bond J. Am. Chem. Soc. 16 1994 10860 10869
46. S. Song, N.A. Shackel, X.M. Wang, K. Ajami, G.W. McCaughan, and M.D. Gorrell Discoidin domain receptor 1: isoform expression and potential functions in cirrhotic human liver Am. J. Pathol. 178 2011 1134 1144
47. N. Tamura, Y. Ogawa, H. Chusho, K. Nakamura, K. Nakao, M. Suda, M. Kasahara, R. Hashimoto, G. Katsuura, M. Mukoyama, H. Itoh, Y. Saito, I. Tanaka, H. Otani, and M. Katsuki Cardiac fibrosis in mice lacking brain natriuretic peptide Proc. Natl. Acad. Sci. U. S. A. 97 2000 4239 4244
48. J.U. Tilan, C. Lu, S. Galli, E. Izycka-Swieszewska, J. Earnest, A. Shabbir, L.M. Everhart, S. Wang, S. Martin, M. Horton, A. Mahajan, D. Christian, A. O'Neill, H. Wang, T. Zhuang, M. Czarnecka, M.D. Johnson, J.A. Toretsky, and J. Kitlinska Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects Oncotarget 4 2013 2487 2501
49. A. Tsuchiya, W.Y. Lu, B. Weinhold, L. Boulter, B.M. Stutchfield, M.J. Williams, R.V. Guest, S.E. Minnis-Lyons, A.C. MacKinnon, D. Schwarzer, T. Ichida, M. Nomoto, Y. Aoyagi, R. Gerardy-Schahn, and S.J. Forbes Polysialic acid/neural cell adhesion molecule modulates the formation of ductular reactions in liver injury Hepatology 60 2014 1727 1740
50. Uitte de Willige, S., Malfliet, J.J., Janssen, H.L., Leebeek, F.W., Rijken, D.C., Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis, (2013) 2029-2036.
51. A.M. Vollmar, G. Paumgartner, and A.L. Gerbes Differential gene expression of the three natriuretic peptides and natriuretic peptide receptor subtypes in human liver Gut 40 1997 145 150
52. X.M. Wang, D.M. Yu, G.W. McCaughan, and M.D. Gorrell Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line Hepatology 42 2005 935 945
53. K.H. Williams, A.J. Vieira de Ribeiro, E. Prakoso, A. Veillard, N.A. Shackel, B. Brooks, Y. Bu, E. Cavanagh, J. Raleigh, S.V. McLennan, G.W. McCaughan, F.M. Keane, A. Zekry, M.D. Gorrell, and S.M. Twigg Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: a dual cohort cross-sectional study J. Diabetes 7 2015 809 819
54. K.H. Williams, A.J. Vieira de Ribeiro, E. Prakoso, A.S. Veillard, N.A. Shackel, Y. Bu, B. Brooks, E. Cavanagh, J. Raleigh, S.V. McLennan, G.W. McCaughan, W.W. Bachovchin, F.M. Keane, A. Zekry, S.M. Twigg, and M.D. Gorrell Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity Diabetes Res. Clin. Pract. 108 2015 466 472
55. D.M.T. Yu, T.-W. Yao, S. Chowdhury, N.A. Nadvi, B. Osborne, W.B. Church, G.W. McCaughan, and M.D. Gorrell The dipeptidyl peptidase IV family in cancer and cell biology FEBS J. 277 2010 1126 1144
56. D.M. Yu, K. Ajami, M.G. Gall, J. Park, C.S. Lee, K.A. Evans, E.A. McLaughlin, M.R. Pitman, C.A. Abbott, G.W. McCaughan, and M.D. Gorrell The in vivo expression of dipeptidyl peptidases 8 and 9 J. Histochem. Cytochem. 57 2009 1025 1040
57. L. Zhang, M.S. Bijker, and H. Herzog The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer Pharmacol. Ther. 131 2011 91 113